ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Dr. Ou at ALKtALK
Dr. Ignatius Sai-Hong Ou – Professor in Hematology-Oncology, Medical Oncology University of California, Irvine Editor-in-Chief of Lung Cancer: Targets and Therapy Associate Editor of Journal of Thoracic Oncology Question: We want to know a little about you. What brought you to study ALK? I was just a young aimless attending (MD) in 2007. I was…
-
Fundraising Guide and Tips for Lung Cancer Awareness Month
About Lung Cancer Awareness MonthNovember is Lung Cancer Awareness Month (LCAM) — an excellent time of year to raise awareness and funds for research. LCAM is ALK Positive’s largest fundraising campaign of the year. We’ve set a goal to raise $1,000,000 in 2021. A huge thank you to the generous match donors who have pledged…
-
International Ambassadors Survey- ALK Life Study
An informal survey was conducted with our ALK International Ambassadors, volunteers from various countries who are passionate about sharing their experiences with others. A total of 22 countries were represented in this survey. In addition to the US, European nations were well represented, as were Australia and New Zealand. There was a notable lack of…
-
ALK-positive Clinical Trials are not just for people in the United States
If you are at diagnosis or at a juncture in treatment, an ALK-positive lung cancer clinical trial may help you receive state of the art treatment. Although many clinical trials for ALK-positive lung cancer have sites in the US, ALK Positives around the world have multiple clinical trial options. An exciting trial outside the US…
-
Are there any new Clinical Trials recruiting for ALK-positive lung cancer?
Clinical trials for more advanced ALK inhibitors, like the TPX-131 study recruiting in Australia and the US, are exciting because they improve on drugs we know work well for ALK-positive lung cancer. However most clinical trials of new ALK treatments in the US and Europe involve combination therapies, designed to overcome ALK inhibitor resistance. As…
-
Gilteritinib overcomes Lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms so far for resistance. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL to…
-
So what about immunotherapy?
The hot phrase in cancer treatment is immunotherapy right now. What does it mean for ALK+patients? Sometimes, you hear that immunotherapy does not work? But why are we trying to fund and are funding vaccines? Don’t vaccines work with the immune system? This short summary is to clarify these questions for you. There is an…
-
Dr. Vincent Lam at ALKtALK
Director, Esophageal Cancer Research Program, Assistant Professor of Oncology Expertise: Esophageal Cancer & Lung cancer Dr Lam: I am so excited to join your conversation tonight on a Sunday evening. I’m scrolling through five pages of people on the zoom call. It’s just amazing to see how committed and engaged you all are. That’s a…